Dewpoint Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
451 D St Ste 104, Boston, Massachusetts,...Phone Number
(617) 914-8448Website
www.dewpointx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Dewpoint Therapeutics
Dewpoint is the leading biotech company in the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. The realization that a vast range of conditions are regulated by or arise from the dysfunction of condensates has provided new possibilities for modulating the function of high-value targets previously deemed undruggable, opening unexplored avenues to identify hundreds of novel therapeutic targets. Dewpoints proprietary AI/ML-powered state-of-the-art platform underlies a drug discovery pipeline that spans multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases.Explore more
Dewpoint Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dewpoint Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Dewpoint Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Dewpoint Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Dewpoint Therapeutics has new funding data
Product Launch: Get notified when Dewpoint Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Dewpoint Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Dewpoint Therapeutics recently announced quarterly report
Check out if Dewpoint Therapeutics is spiking on competitors!
Dewpoint Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Dewpoint Therapeutics
Compare insights from companies similar to Dewpoint Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dewpoint Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dewpoint Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dewpoint Therapeutics.
Dewpoint Therapeutics financials insights
Gather financial insights about Dewpoint Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$60M
2020
Series B
$77M
2022
Series C
$150M
2025
Private Equity
$59.1M
Dewpoint Therapeutics Tech Stack
A closer look at the technologies used by Dewpoint Therapeutics
Most Recent Scoops
Person-Based
Product Development, Medical Research, Pharmaceuticals
Person-Based
Product Development, Product Management, Pharmaceuticals, Clinical Operations, Operations
Person-Based
Person-Based
Person-Based
Dewpoint Therapeutics News & Media
Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate
Dewpoint Therapeutics selects a first-in-class small molecule development candidate for multiple cancers in which MYC dependence is a central driver.Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer
Dewpoint doses first patient in Phase 1a/2a trial of DPTX3186, an FDA Fast Track, Orphan-designated beta-catenin modulator for advanced solid tumors.Dewpoint Therapeutics Announces TDP-43 Condensate Modulator Development Candidate for Treatment of ALS and Related Neurodegenerative Diseases
First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates in ALS, FTD and traumatic brain injury.Dewpoint Therapeutics Launches Initiative to Build Viral Condensate Phenomics Atlas for HPV
Dewpoint Therapeutics launches Gates Foundation-funded initiative to build and share viral condensate phenomics atlas for HPV.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Dewpoint Therapeutics
Sign Up For FreeTo access detailed company insights
Dewpoint is the leading biotech company in the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. The realization that a vast range of conditions are regulated by or arise from the dysfunction of condensates has provided new possibilities for modulating... Read More
